Capricor Therapeutics (CAPR) Other financing activities (2012 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Other financing activities of $1.5 million for Q1 2026, up 2820.64% year-over-year from $50354.0 in Q1 2025, and down 87.52% quarter-over-quarter from $11.8 million in Q4 2025.
Capricor Therapeutics (CAPR) Other financing activities (2012 - 2026) Analysis & Trends
Capricor Therapeutics' Other financing activities history runs 15 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Other financing activities rose 2820.64% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $13.3 million (up 3044.13% YoY), while the FY2025 annual figure was $11.9 million, up 2534.18% from the prior year.
- Other financing activities for Q1 2026 stood at $1.5 million, down from $11.8 million in the prior quarter.
- The five-year high for Other financing activities was $11.8 million in Q4 2025, with the low at $1518.0 in Q3 2022.
- The 5-year median for Other financing activities is $26890.0 (2022), against an average of $988062.4.
- The sharpest annual moves came in 2024 and 2025: Other financing activities soared 8091.48% in 2024, then plunged 94.26% in 2025.
- Capricor Therapeutics' Other financing activities stood at $26315.0 in 2022, then tumbled by 88.5% to $3027.0 in 2023, then jumped by 8091.48% to $247956.0 in 2024, then surged by 4651.44% to $11.8 million in 2025, then sank by 87.52% to $1.5 million in 2026.
- Business Quant data shows CAPR's Other financing activities at $1.5 million in Q1 2026, $11.8 million in Q4 2025, and $6950.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 11.78 Mn |
| Dec 31, 2025 | 11.78 Mn |
| Sep 30, 2025 | 6,950.00 |
| Sep 30, 2025 | 6,950.00 |
| Jun 30, 2025 | 19,580.00 |
| Jun 30, 2025 | 19,580.00 |
| Mar 31, 2025 | 50,354.00 |
| Mar 31, 2025 | 50,354.00 |
| Dec 31, 2024 | 247,956.00 |
| Dec 31, 2024 | 247,956.00 |
| Sep 30, 2024 | 120,995.00 |
| Sep 30, 2024 | 120,995.00 |
| Dec 31, 2023 | 3,027.00 |
| Dec 31, 2023 | 3,027.00 |
| Jun 30, 2023 | 57,679.00 |
| Jun 30, 2023 | 57,679.00 |
| Mar 31, 2023 | 3,895.00 |
| Mar 31, 2023 | 3,895.00 |